Genmab — November 2020

Helge_LarsenPI-redaktør

Sujit k, 2020-11-27 15:08:27
What are the potential readout to look in 2021? (on prostate cancer agents )

Helge_LarsenPI-redaktør

Sujit k, 2020-11-27 15:10:01
Y the half life of JNJ-8081 is predicted ~5days, whereas other DuoBody format has half life upto 25 days

Helge_LarsenPI-redaktør

Sujit k, 2020-11-27 15:22:38
Please speak something about the JnJ PSMA molecule in your Duobody format?

Helge_LarsenPI-redaktør

aarfaei, 2020-11-27 15:20:03
Was the primary issue with enapotamab vedotin efficacy or sofety?

Helge_LarsenPI-redaktør

peter12, 2020-11-25 21:30:04
When will we see candidates using Curevac mRNA technology in the clinic ?

Helge_LarsenPI-redaktør

Der er flere spøgsmål endnu, men da det er dobbeltpost af samme spørgsmål fra andre brugere som er besvaret af Jan, poster jeg ikke disse.

peter12

Tak Helge Hvordan skal dette svar forstås. Skal der stå "No" eller "Now" ? JdW:
So now picking and choosing from Genmab's proprietary product pipeline, but newly creating product options in the partnership.

E_L

pretty certain that that is a typo and should be a NO @peter.

E_L

My guess for the moment is that we will at least see something utilizing AbbVie’s ADC technology, which Jan recently called ADC 3.0. My gutfeel is that he thinks it is better as ADCT's technology or even Seagen's and that it could be one of the reasons CamiT is not further persued. purely guessing offcourse.

E_L

On GB / Hexacd38; 1. competition does not stop working and Dara may not remain the best cd38 forever. 2. Dara patent will roll off at some point; hexa would give a new patentlife to the the cd38 business 3. hexa could sigfnificantly enlarge their cd38 business if it works in other disease areas (and Jan has several times hinted that that could be the case)

E_L

btw GB; you asked on amyloidosis; even though the market is much smaller, I would hope for a much faster uptake and immediately into first line as it really seems to be such a good drug for this disease

GeorgeBest

Thanks E L, also my thoughts. Will keep Sarclisa and CarT on the backfoot. But on the other hand JNJ already have CarT through Legend!

E_L

possibly for later lines, or, as they have inidicated,
in combo with cd38

E_L

Btw on amyloidosis, some say the disease size is seriously underestimated;

E_L

as the symptons do not always easily point to amyloidosis,

E_L

many patients are never propperly diagnosed as having it

E_L

I have seen articles therefore stating that market could be quit a bit larger. JNJ also indicated this at some point and said would put efforts into doctors education

E_L

ImmunoPrecise was mentioned in a question but not really answered...

E_L

I think Jan would have directed Sujit k, to JNJ for all his questions...

E_L

Note that JNJ-70218902
is also recently new directed at prostate cancer https://clinicaltrials.gov/ct2/show/NCT04397276